首页|Second Affiliated Hospital of Guilin Medical University Reports Findings in Bladder Cancer (A Machine Learning Computational Framework Develops a Multiple Programmed Cell Death Index for Improving Clinical Outcomes in Bladder Cancer)
Second Affiliated Hospital of Guilin Medical University Reports Findings in Bladder Cancer (A Machine Learning Computational Framework Develops a Multiple Programmed Cell Death Index for Improving Clinical Outcomes in Bladder Cancer)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on Oncology - Bladder Cancer is the subject of a report. According to news reporting out of Guangxi, People's Republic of China, by NewsRx editors, research stated, "Comprehensive action patterns of programmed cell death (PCD) in bladder cancer (BLCA) have not yet been thoroughly investigated. Here, we collected 19 different PCD patterns, including 1911 PCD-related genes, and developed a multiple programmed cell death index (MPCDI) based on a machine learning computational framework." Our news journalists obtained a quote from the research from the Second Affiliated Hospital of Guilin Medical University, "We found that in the TCGA-BLCA training cohort and the independently validated GSE13507 cohort, the patients with high-MPCDI had a worse prognosis, whereas patients with low-MPCDI had a better prognosis. By combining clinical characteristics with the MPCDI, we constructed a nomogram. The C-index demonstrated that the nomogram was significantly more accurate compared to other variables, including MPCDI, age, gender, and clinical stage. The results of the decision curve analysis demonstrated that the nomogram had a better net clinical benefit compared to other clinical variables. Subsequently, we revealed the heterogeneity of BLCA patients, with significant differences in terms of overall immune infiltration abundance, immunotherapeutic response, and drug sensitivity in the two MPCDI groups. Encouragingly, the high-MPCDI patients showed better efficacy for commonly used chemotherapeutic drugs than the low-MPCDI patients, which suggests that MPCDI scores have a guiding role in chemotherapy for BLCA patients."
GuangxiPeople's Republic of ChinaAsiaBladder CancerCancerCyborgsDrugs and TherapiesEmerging TechnologiesGeneticsHealth and MedicineMachine LearningOncology
NETL
NSTL
